MA45340A - Acides nucléiques du récepteur des androgènes et leurs utilisations - Google Patents
Acides nucléiques du récepteur des androgènes et leurs utilisationsInfo
- Publication number
- MA45340A MA45340A MA045340A MA45340A MA45340A MA 45340 A MA45340 A MA 45340A MA 045340 A MA045340 A MA 045340A MA 45340 A MA45340 A MA 45340A MA 45340 A MA45340 A MA 45340A
- Authority
- MA
- Morocco
- Prior art keywords
- nucleic acids
- androgen receptor
- receptor nucleic
- androgen
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317116P | 2016-04-01 | 2016-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA45340A true MA45340A (fr) | 2019-02-06 |
Family
ID=59965243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA045340A MA45340A (fr) | 2016-04-01 | Acides nucléiques du récepteur des androgènes et leurs utilisations |
Country Status (4)
Country | Link |
---|---|
US (2) | US20170306334A1 (fr) |
EP (1) | EP3436583A4 (fr) |
MA (1) | MA45340A (fr) |
WO (1) | WO2017173300A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3074320A1 (fr) * | 2017-09-14 | 2019-03-21 | Arrowhead Pharmaceuticals, Inc. | Agents d'arni et compositions destinees a inhiber l'expression d'analogue de l'angiopoietine 3 (angptl3) et procedes d'utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1071753A2 (fr) * | 1998-04-20 | 2001-01-31 | Ribozyme Pharmaceuticals, Inc. | Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique |
JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
US20050164970A1 (en) * | 2003-12-22 | 2005-07-28 | University Of Kansas Medical Center | Method for treating prostate cancer using siRNA duplex for androgen receptor |
EP2591104A4 (fr) * | 2010-07-06 | 2014-09-03 | Dicerna Pharmaceuticals Inc | Procédés et compositions pour l'inhibition spécifique du récepteur des androgènes par arn double brin |
EP2632472B1 (fr) * | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Inhibition facilitée par l'interférence d'arn de l'expression d'un gène au moyen d'acides nucléiques interférents courts (sina) |
WO2013036879A1 (fr) * | 2011-09-08 | 2013-03-14 | Gradalis, Inc. | Compositions et méthodes de traitement du cancer de la prostate |
CN105861503A (zh) * | 2011-11-18 | 2016-08-17 | 阿尔尼拉姆医药品有限公司 | 修饰的RNAi试剂 |
PT2978845T (pt) * | 2013-03-27 | 2020-08-03 | Isarna Therapeutics Gmbh | Oligonucleótidos de tgf-beta modificados |
-
0
- MA MA045340A patent/MA45340A/fr unknown
-
2017
- 2017-03-31 US US15/476,293 patent/US20170306334A1/en not_active Abandoned
- 2017-03-31 WO PCT/US2017/025428 patent/WO2017173300A1/fr active Application Filing
- 2017-03-31 EP EP17776792.8A patent/EP3436583A4/fr active Pending
-
2021
- 2021-10-21 US US17/507,669 patent/US20220033434A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3436583A4 (fr) | 2019-12-11 |
EP3436583A1 (fr) | 2019-02-06 |
US20170306334A1 (en) | 2017-10-26 |
US20220033434A1 (en) | 2022-02-03 |
WO2017173300A1 (fr) | 2017-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
DK3433368T3 (da) | Transreplikerende rna | |
MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
BR112016016289A2 (pt) | heteroaris e usos dos mesmos | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
MA46945A (fr) | Exopolysaccharides et leurs utilisations | |
MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
MA41495A (fr) | Composés benzoxaborole et leurs utilisations | |
MA46562A (fr) | Anticorps anti-chikv et leurs utilisations | |
MA46901A (fr) | Agents psychotropes et leurs utilisations | |
KR20180084747A (ko) | Galgt2 유전자 치료 방법 및 물질 | |
DK3544752T3 (da) | Træk- og deformationsenhed | |
MA45411A (fr) | Compositions antimalariques et leurs utilisations | |
DK3405631T3 (da) | Indhegningssystem | |
MA41850A (fr) | Nouvelles utilisations pharmaceutiques | |
BR112017018932A2 (pt) | etv2 e usos do mesmo | |
MA41022A (fr) | Ciblage lysosomial et utilisations correspondantes | |
DK3251483T3 (da) | Ophængningsanordning | |
MA44073A (fr) | Raccord anti-sismique | |
DK3245376T3 (da) | Hegnbeslag |